Isomorphic Labs Raises $5 Billion to Accelerate AI Drug Discovery
The Google DeepMind spin-off aims to advance drug candidates into clinical trials with backing from major investment firms.
Isomorphic Labs has secured $5 billion in a Series C funding round. The company utilizes artificial intelligence simulation models to design new drugs and explore complex areas of chemistry.
The investment was led by Greenoaks and Sequoia Capital. New investors such as Andreessen Horowitz participated in the round alongside previous backers including Alphabet, Thrive Capital, and Temasek.
The company's technology is based on the AlphaFold model, which predicts protein structures from genetic sequences. This work earned a Nobel Prize in Chemistry for founders Demis Hassabis and John Jumper.
The funds will be directed toward the development of its drug design engine and expansion into new categories of medicine. The company has already achieved positive preclinical results in oncology and immunology.
Isomorphic Labs maintains strategic partnerships with pharmaceutical giants such as Eli Lilly, Novartis, and Johnson & Johnson. The current focus is to advance its therapeutic programs into human clinical trials.
Spotted an error? Write to suporte@criptoico.com.br.